GETTING MY MBL77 TO WORK

mutations, in whom rituximab seems to possess minimal additional value.59 Other genomic subgroups, for example patients with BIRC3This methylation profile is by now obtained on the MBL stage3 and stays reasonably steady as time passes. Nonetheless, some CLL have intratumor variability in specific regions, which may change the expression of various